By Jake B. Guinto, PhD, Manager, Oncology Drugs & Biologics
On Friday, September 14th and Saturday, September 15th, the National Comprehensive Cancer Network® (NCCN®) hosted the NCCN 7th Annual Congress: Hematologic Malignancies™ in New York City. Speakers included expert clinicians from a number of NCCN Member Institutions, including City of Hope Comprehensive Cancer Center, Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Duke Cancer Institute, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Memorial Sloan-Kettering Cancer Center, Moffitt Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MD Anderson Cancer Center, and UCSF Helen Diller Family Comprehensive Cancer Center.
During the two-day event, speakers discussed a number of topics related to hematologic malignancies, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), current standard-of-care therapies, ongoing clinical studies, future promising therapies, various case studies, and other issues relating to these cancers. Andrew D. Zelenetz, MD, PhD, of Memorial Sloan-Kettering Cancer Center and chair of the NCCN Guidelines Panel for non-Hodgkin's lymphomas, moderated the Congress and gave a presentation on positron emission tomography (PET) and its role in staging, response evaluation, therapeutic decision-making, and post-treatment surveillance in the management of patients with lymphomas. In addition, esteemed faculty discussed a number of topics on Friday, including chronic myelogenous leukemia, Philadelphia chromosome-positive (Ph+) leukemias, acute lymphoblastic leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and Hodgkin lymphoma.
Saturday's sessions were equally informative. The morning began with two presentations on multiple myeloma, followed by a presentation on hematopoietic stem cell mobilization. A module on supportive care concluded the Congress, with presentations focusing on erythropoiesis-stimulating agents and their role in anemia, new and emerging agents used to prevent and treat venous thromboembolic disease, and the management of idiopathic thrombocytopenic purpura.
Over 500 people attended the Congress, including clinicians, nurses, pharmacists, and other health care providers. In addition to providing a forum for staying abreast on the latest advances in hematologic cancer care, the NCCN 7th Annual Congress: Hematologic Malignancies™, in conjunction with the products, technologies, and programs showcased by exhibitors, provided attendees with an enlightening and educational experience.